ClinicalTrials.gg
Not yet recruitingNCT06670417Updated Nov 5, 2024

Low-level Laser Therapy Versus Offloading Exercises on Foot Ulcer Healing in Patients with Type 2 Diabetes

An interventional study of Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light and Buerger Allen exercise in Diabetic Foot Ulcer (DFU), sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 45 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Diabetic Foot with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · Egypt.

Planned enrollment
9th of 26
60 · median 49
Started
2024
with 4 others
No phase
21 of 30
6 open now
Registered
19th of 30
by date
Lead sponsor
8 of 30
Cairo University

Among the 30 studies in Diabetic Foot with a site in Egypt, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2024, is one of 21 with no phase, and was the 19th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

7 of the 30 studies in Diabetic Foot with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Foot with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect of extravascular Low-level laser therapy (LLLT) versus offloading exercises on foot ulcers healing (DFUs) in type 2 diabetic patients. could include sixty patients with type 2 diabetes associated with diabetic foot ulcer as a complication, their ages ranging from 45 - 55 years. Patients will be selected from Faculty of Medicine (Kasr Al-Aini) Cairo University. They will be referred by the physician after a complete medical evaluation. . The main question it aims to answer is there any significant difference between extravascular low-level laser therapy and offloading exercise on diabetic foot ulcer healing in type 2 diabetic patients ?

After clinical assessment patients will be randomly allocated into three groups equal in number:

Group (A) (Experimental A): will receive extravascular low level laser therapy LLLT (laser watch device) combined with their prescribed hypoglycaemic medications(oral and insulin) and usual wound care for 12 weeks (3 sessions/ week).

Group (B) (Experimental B): will receive Offloading exercise inform of burger allen exercise combined with their prescribed hypoglycaemic medications(oral and insulin) and usual wound care for 12 weeks (3 sessions/ week).

Group (C) Control group will receive their prescribed hypoglycaemic medications(oral and insulin) and usual wound care only for 12 weeks (3 sessions/ week).

03

Conditions studied

  • Diabetic Foot Ulcer (DFU)

Browse trials for

Keywords

  • Low level laser
  • Diabetic Foot Ulcer
  • Blood glucose level
04

Who can participate

Ages eligible
45 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 25-34.9 kg/m2.
  • (HbA1c) >7 %.
  • ABP index absolute normal (1-1.3)
  • Patient with polyneuropathy.
  • Patient suffer from diabetes more than 5 years.
  • Patient has chronic unhealed diabetic ulcer from 4 weeks up to 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of hypo- hyperglycemic coma.
  • Uncontrolled cardiovascular complications.
  • , Anemia, Hemorrhagic diseases.
  • Cardiac peace maker.
  • Deep venous thrombosis.
  • Osteomyelitis.
  • Patients with Monckeberg sclerosis.
  • Photosensitivity to laser.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group (A) (Experimental A): will receive extravascular low level laser therapy LLLT (laser watch dev

    Device: Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light

  • Experimental
    B) (Experimental B): will receive Offloading exercise inform of burger allen exercise combined with

    Other: Buerger Allen exercise

  • Experimental
    (C) Control group will receive their prescribed hypoglycaemic medications(oral and insulin) and usua

    Other: Regular wound care

Interventions

  • DeviceLow level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light

    Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light. It provides 18 individual laser beams used for extravascular blood irradiation (transcutaneous) through radial and ulnar vessels at the wrist site.

  • OtherBuerger Allen exercise

    Procedure-Keep the Buerger Allen exercise board on the cot. Elevate the lower extremities to an angle of 45 to 90 degree with the help of exercise board. Provided support to the lower extremities to maintain the position. Make the subject to maintain the same position in the same manner until the skin blanches (appears dead white). Lower the feet and the legs below the level of the rest of the body until redness appears (care should be taken that there is no pressure against the back of the knees). Place the legs flat on the bed for a few minutes. Ask the subjects to sit in a relaxed position while each foot is flexed and extended then inverted and everted for 3 minutes till the feet turns entirely pink. Ask the subject to rotate the feet in all the direction. Make the subject to lie quietly for 5 minutes, keeping legs warm with a blanket

  • OtherRegular wound care

    Regular wound care and dressing to the wound and ulcer

06

What researchers measure

Primary outcomes

  1. wound surface area

    Time frame: From enrollment to the end of treatment at 2 weeks

  2. Glycated hemoglobin HbA1c

    Time frame: From enrollment to the end of treatment at 12weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Dec 2025, 13 months later.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 13 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 1, 2024
StartEst.
Nov 30, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670417
Lead sponsor
Cairo University
Responsible party
Heba afifi (lecturer Assistant, Cairo University) — Principal investigator
First posted
Nov 1, 2024
Start date
Nov 30, 2024 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Nov 5, 2024

Study contacts

Hebatullah Emad lecturer Assistant
Contact
hebaemad2005@hotmail.com
002 1066103900
Hend Abdel Lecturer
Contact
Drhendpt@cu.edu.eg
002 1115507195

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion